BWA
AVXL icon

Basecamp Wealth Advisors’s Anavex Life Sciences AVXL Stock Holding History

Basecamp Wealth Advisors’s Portfolio AVXL Stock Details AVXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$41 Buy
16
+15
+1,500% +$44 ﹤0.01% 1810
2026
Q1 		$3 Buy
+1
New +$4 ﹤0.01% 2007

Other funds holding AVXL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SF
Summit Financial Parsippany, New Jersey $9.12B AUM 27.44% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Basecamp Wealth Advisors's AVXL Position: Q2 2026 in Review

Basecamp Wealth Advisors increased its Anavex Life Sciences (AVXL) stake by 1,500% in Q2 2026, buying an estimated $44 and bringing the position to 16 shares worth $41. The position accounts for ﹤0.01% of the portfolio, ranked #1810.

Basecamp Wealth Advisors first reported a position in AVXL in Q1 2026 and has held it in 2 quarters since. 179 funds tracked by Wall St. Rank hold AVXL as of Q2 2026.

  • Basecamp Wealth Advisors held 16 shares of Anavex Life Sciences worth $41 as of Q2 2026.
  • Basecamp Wealth Advisors bought 15 Anavex Life Sciences shares in Q2 2026, an estimated $44.
  • Anavex Life Sciences made up ﹤0.01% of Basecamp Wealth Advisors's portfolio in Q2 2026, its #1810 holding.
  • Basecamp Wealth Advisors first reported a position in Anavex Life Sciences in Q1 2026 and has held it in 2 quarters since.
  • 179 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q2 2026.

Based on Basecamp Wealth Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.